Home > Healthcare & Medical Devices > Gene Editing Market

Gene Editing Market Size by Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENs) and End-user (Biotech and Pharma Companies, Contract Research Organizations (CROs), Research Institutes), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030

  • Report ID: GMI810
  • Published Date: May 2022
  • Report Format: PDF

Industry Overview

Gene Editing Market size surpassed USD 5.4 Bn in 2021 and is expected to witness a 15.5% CAGR from 2022 to 2030 owing to an increasing technological advancement driven by the rapidly evolving CRISPR technology with its wide range of applications for gene editing.
 

gene editing market outlook

Get more details on this report - Request Free Sample PDF
 

This technology is mainly used to gain accessibility of genetically modified crops by delivering gene editing reagents in the plants. Moreover, this technology is also accessible for genetically modified animals with application for agricultural purposes and biomedical fields.
 

The impact of COVID-19 on the gene editing market share is observed to be positive. Recently, in 2020, SHERLOCK CRISPR SARS-CoV-2 test kit was granted by Emergency Use Authorization from the FDA. This is due to the programming by CRISPR for detecting genetic pattern of SARS-CoV-2 by utilising gRNA. In case target is detected in a sample, the CRISPR is activated and released.
 

Gene Editing or genome editing is mainly used to change an organism’s DNA by various group of technologies. This method allows genetic material to be replaced, added, or removed at spotted locations in the genome. Therefore, various editing approaches have been developed for its application in the industry. Gene editing is also used for prevention and treatment of human diseases such as cystic fibrosis, sickle cell diseases, HIV infection, cancer, and others.
 

Rising funding for genetic research will propel the market progression

Rising funding for genetic study in developed regions including North America will drive the gene editing market growth over the forecast period. In the U.S., more than 20 federal agencies funded research and development government firms to produce useful materials, devices, and methods. Moreover, the U.S. government funds various research firms that help in the development and manufacturing of drug discovery for various rare genetic diseases. For instance, the National Human Genome Research Institute supports research programs and project to advance in the field of genomics.
 

Similarly, The National Institutes of Health (NIH), a part of the U.S. government’s Health and Human Services and nation’s medical research agency is responsible for research activities in genetics and biomedical. Recently in 2021, NIH funded around USD 1.6 million to the Arizona State University and Bayer College of Medicine for evaluating recent advancements in human genome editing. Recently developed drugs specifically for the treatment of genetic disorders have decreased the mortality rate that will boost the gene editing market growth in the expected future.
 

Increasing demand for CRISPR/Cas9 technology will favour the industry growth over the forecast period

gene editing market by technology

Get more details on this report - Request Free Sample PDF
 

Based on technology, the market is divided into Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, and TALENs, others. Among them, the CRISPR/Cas9 segment is expected to account for around 15.6% CAGR through 2030. This technological segment is simple, easy to use, and inexpensive compared to other techniques. Increasing demand for CRISPR/Cas9 for the investigation of genome to identify genetic disorders and its drug discovery will increase the opportunity of gene editing market segment.
 

CRISPR technology can be used for the treatment of cancer through gene-editing technology. Key market players such as Caribou Biosciences, Takara Bio, Thermo Fisher Scientific are focusing on their research and development activities for adapting innovations in the CRISPR/Cas9 technology.
 

Rising application of cell line engineering will accelerate the overall market expansion

editing market by application

Get more details on this report - Request Free Sample PDF
 

Based on application, the market is segmented into animal genetic engineering, cell line engineering, and plant genetic engineering as well as others. Among these, the cell line engineering market accounted for over USD 2.2 billion in 2021. Cell-line engineering is widely used for stem cell based-cell therapy treatment.
 

Rapid development and advancement of genome editing technologies have enabled introduction of genetic changes into induced pluripotent stem cells (iPSCs) along with corrections of disease-causing genetic mutations. Recent adaptation and advancement in editing techniques including Zinc Finger Nucleases (ZFNs), CRISPR/Cas, and TALENs have made cell engineering cheaper and easy.
 

Increasing focus on developing novel gene editing technologies will offer significant market growth opportunities 

The market based on end-user is segmented into contract research organizations (CROs), biotech and pharma companies, and research institutes. The biotech and pharma companies segment accounted for over 45.5% market share in 2021. Growing focus on development of new gene editing technologies by various biotechnology companies will increase the segmental growth.
 

For instance, Horizon Discovery aimed to create genome editing tool with advanced technology for accurate and efficient functional genes. One of the products launched by the company includes Edit-R algorithm CRISPR guide RNAs to edit the targeted gene. In recent years, technology advancements have enabled the market players to transform gene editing tools that are efficient for the treatment of a genetic disorders.
 

Growing adoption of gene editing techniques in North America region will augment the market progression

gene editing market by region

Get more details on this report - Request Free Sample PDF
 

North America captured around 38% of the market share in 2021 and is expected to grow significantly during the forecast years due to the rise in number of rare diseases in the U.S. and Canada. According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. Therefore, the demand for development of drugs to cure rare diseases increases by adaption of new gene editing tools and technologies. Also, presence of leading industry players in North America will foster the gene editing market growth.
 

Innovative strategies by key market players will upsurge growth opportunities in the market

Some of the leading market players operating in the gene editing industry include Horizon Discovery Ltd., Sangamo Therapeutics, Inc., GenScript, Integrated DNA Technologies, Inc., Precision Biosciences, Bearn Therapeutics, Thermo Fisher Scientific Inc., Intellia Therapeutics, Inc., CRISPR Therapeutics, Caribou Biosciences, Inc. and others.
 

 These industry participants are implementing various growth strategies with increased innovations and technology improvements to sustain market competition in gene editing market. These market players are undertaking several organic and inorganic growth strategies to garner higher market revenue in gene editing market.
 

Some of the recent industry developments:

  • In June 2021, Allele Biotechnology and Alpine BioTherapeutics Corporation announced an agreement for developing induced pluripotent stem cells for treatment of retinal diseases. This strategy assisted the company in developing advanced product portfolio.
     
  • In May 2020, Caribou Science entered into commercial and clinical license agreement with MaxCyte. The agreement was aimed to gain exclusive rights to use MaxCyte’s flow electroporation technology as well as ExPERT platform. This strategy advanced Caribou’s gene-edited allogenic T cell therapy programs and expanded their corporate relations in gene editing market.
     

The gene editing market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:

By Application

  • Cell line engineering
  • Animal genetic engineering
  • Plant genetic engineering
  • Others

By Technology

  • CRISPR/Cas9
  • Zinc Finger Nucleases (ZFNs)
  • TALENs
  • Others

By End-user

  • Biotech and pharma companies
  • Contract research organizations (CROs)
  • Research institutes

The above information is provided for the following regions and countries:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Poland
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The gene editing industry is slated to surpass USD 19.9 billion by 2030 and is poised to record a 15.5% CAGR from 2022 to 2030 on account of the rise in technological advancements and the rapidly evolving CRISPR technology.

The CRISPR/Cas9 technology segment in the gene editing market is poised to record a 15.6% CAGR through 2030 owing to its benefits, including simplicity, easy use, and affordability.

The biotech and pharma companies end-user segment captured close to 45.5% of the gene editing market share in 2021 due to the rising focus on the development of new gene editing technologies.

The gene editing industry revenue from the cell line engineering application segment had crossed USD 2.2 billion in 2021 due to the swift developments and advancements in genome editing technologies.

North America held more than 38% of the gene editing industry share in 2021 and will record a significant CAGR through 2030 due to the higher burden of rare diseases in the U.S. and Canada.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 10
  • Tables & Figures: 117
  • Countries covered: 20
  • Pages: 130

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount